Contributions
Abstract: EP1654
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Introduction: Teriflunomide (TER) has been effective and secure in multiple sclerosis (MS) clinical trials (CTs) recruiting mainly naïve patients. Some real-world evidence is now available suggesting TER is even effcient for patients who differ mostly from CTs, but the follow-up is still too short.
Objective: To analyze the efficacy and tolerability of TER with respect to previous disease modifiyng therapy (DMT).
Methods: We retrospectively recorded clinical and radiological data from 255 patients who underwent teriflunomide. Comparisons were made using t test or sign test for numerical variables, and χ2 for categorical variables.
Results: A total of 255 patients´ records (mean of age=45.27±11.5y) who were on treatment (13.1±6.7mo) from december 2014 to march 2017; 184 females) were reviewed. MS types (n=242) were classified as relapsing-remiting, and 13 as progressive forms (mean disease duration=10.92±8.5y). Most (n=171) were on at least one DMF (43.13% from IF), 37 patients switched to TER because of inefficacy, and 134 for intolerance. Annual relapse rate (ARR) was significatively reduced in 191 patients completing at least 1y on treatment (basal ARR=0.950±0.7; 1y ARR=0.246±0.5; p< 0.0001), 2ndy ARR=0.5±0.6 (n=37; p=0.006). Multivariate regression, adjusted for sex, and age, disclosed no differences for TER response after 12 mo by previous treatment (absolute ARR reduction=0.588±0.09 for naïve patients, and 0.673±0.1 for switchers). After 1y, basal EDSS (mean=1.992±1.4) remained stable in 73.71% (p=0.093), and in 84.12% in the 2ndy (p=0.028). MRI scans (basal n=236; 1sty n=77) showed no new T2 lesions in 61.44%. Number of Gd+T1 lesions decresed after 1y (p=0.066). No serious adverse events were recorded.
Conclusions: In real word, most patients switched from other therapies to TER, and they were older. than in CTs. Even in this scenario, TER was clinical and radiologically effective. We observed a further potential benefit for those swhitching from other therapies, mainly IFB and GA, independently of the reason for switching.
Disclosure:
Villafani J has received honoraria for speaking from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme, Roche.
Peña J, has received honoraria for speaking from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme.
Oliva P has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme, Roche
Ares A has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme.
Hernandez L has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme.
Perez D has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme.
Solar DM has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme, Roche
Suarez R has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme.
Fernandez-Uria D has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme, Roche.
Lara L has nothing to disclose
Quintanilla GQ for speaking from Novartis and Sanofi Genzyme.
Rodriguez E has received honoraria from Sanofi Genzyme.
Oterino A has received honoraria for speaking from Biogen Inc., TEVA, Almirall, MSD Novartis, Sanofi Genzyme, Roche, Allergan.
Abstract: EP1654
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Introduction: Teriflunomide (TER) has been effective and secure in multiple sclerosis (MS) clinical trials (CTs) recruiting mainly naïve patients. Some real-world evidence is now available suggesting TER is even effcient for patients who differ mostly from CTs, but the follow-up is still too short.
Objective: To analyze the efficacy and tolerability of TER with respect to previous disease modifiyng therapy (DMT).
Methods: We retrospectively recorded clinical and radiological data from 255 patients who underwent teriflunomide. Comparisons were made using t test or sign test for numerical variables, and χ2 for categorical variables.
Results: A total of 255 patients´ records (mean of age=45.27±11.5y) who were on treatment (13.1±6.7mo) from december 2014 to march 2017; 184 females) were reviewed. MS types (n=242) were classified as relapsing-remiting, and 13 as progressive forms (mean disease duration=10.92±8.5y). Most (n=171) were on at least one DMF (43.13% from IF), 37 patients switched to TER because of inefficacy, and 134 for intolerance. Annual relapse rate (ARR) was significatively reduced in 191 patients completing at least 1y on treatment (basal ARR=0.950±0.7; 1y ARR=0.246±0.5; p< 0.0001), 2ndy ARR=0.5±0.6 (n=37; p=0.006). Multivariate regression, adjusted for sex, and age, disclosed no differences for TER response after 12 mo by previous treatment (absolute ARR reduction=0.588±0.09 for naïve patients, and 0.673±0.1 for switchers). After 1y, basal EDSS (mean=1.992±1.4) remained stable in 73.71% (p=0.093), and in 84.12% in the 2ndy (p=0.028). MRI scans (basal n=236; 1sty n=77) showed no new T2 lesions in 61.44%. Number of Gd+T1 lesions decresed after 1y (p=0.066). No serious adverse events were recorded.
Conclusions: In real word, most patients switched from other therapies to TER, and they were older. than in CTs. Even in this scenario, TER was clinical and radiologically effective. We observed a further potential benefit for those swhitching from other therapies, mainly IFB and GA, independently of the reason for switching.
Disclosure:
Villafani J has received honoraria for speaking from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme, Roche.
Peña J, has received honoraria for speaking from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme.
Oliva P has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme, Roche
Ares A has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme.
Hernandez L has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme.
Perez D has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme.
Solar DM has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme, Roche
Suarez R has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme.
Fernandez-Uria D has received honoraria from Biogen Inc., TEVA, Novartis, Merck, Sanofi Genzyme, Roche.
Lara L has nothing to disclose
Quintanilla GQ for speaking from Novartis and Sanofi Genzyme.
Rodriguez E has received honoraria from Sanofi Genzyme.
Oterino A has received honoraria for speaking from Biogen Inc., TEVA, Almirall, MSD Novartis, Sanofi Genzyme, Roche, Allergan.